Designing Studies For Post-Treatment Lyme Disease and Other Infection-Associated Chronic Illnesses

September 15, 2026

https://academic.oup.com/brain/article/149/6/1842/8586348

Designing studies for post-treatment Lyme disease and other infection-associated chronic illnesses 

Paul M Arnaboldi, Jacqueline Becker, Avindra Nath, Patricia K Coyle, Andrew Handel, Timothy J Sellati, Maria Gomes-Solecki, Sandra Garcet, Marianne K Henderson, Piper Mullins,… Show more

Brain, Volume 149, Issue 6, June 2026, Pages 1842–1859, https://doi.org/10.1093/brain/awag016

Published: 18 May 2026

Abstract

Infection-associated chronic illnesses (IACIs) encompass a spectrum of poorly understood syndromes often marked by significant neurologic and multisystem symptoms following an infectious event.

This review focuses on several diseases representative of the IACI spectrum. These are post-treatment Lyme disease syndrome (PTLDS), long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and multiple sclerosis (MS). Their clinical and biological complexity, combined with a lack of clear diagnostic criteria and objective available laboratory biomarkers, makes them difficult to distinguish from conditions with overlapping features. This presents challenges for research studies, as well as diagnosis and clinical management. This diagnostic ambiguity, coupled with heterogeneous patient presentations, has led to challenges in research, including misclassification of study participants and inconsistent or irreproducible findings. Some PTLDS research exemplifies these issues, which also extend to other IACIs.

To advance the field, we highlight key methodological refinements and approaches for studying IACIs, including rigorous participant selection, standardized sample collection protocols, and the use of appropriate control groups, including those with microbiologic proof of the initial infection when known and technologically feasible. We also address broader influences on research quality, such as stigma, historical neglect, and the urgency to find treatments, which have contributed to the proliferation of poorly controlled studies and questionable practices. Drawing lessons from past challenges, we propose a path forward grounded in fit-for-purpose methodological rigor to improve scientific understanding and support evidence-based therapeutic development for IACIs. (See link for full article)

________________

**Comment**

I’m not going to do a full write up of this, but am simply going to point out an error right away in paragraph two which states, “antibiotic therapy is effective for clearing the bacterium.” For years research has shown that this is simply not the case with a subset of patients. There are numerous reasons for this including the involvement of coinfections antibiotics won’t touch, and using an ineffective antibiotic, for the wrong duration of time as research has shown many of these pathogens have the ability to sequester in tissues in a dormant state when threatened by treatment only to reemerge later when conditions are favorable. Again, for a vast majority of patients who are infected with multiple pathogens simultaneously, an antiquated and ineffective CDC monotherapy simply will not and can not work.

As I’ve written previously, I take issue with the accepted post-treatment Lyme disease syndrome (PTLDS) moniker since the ‘post treatment’ is based upon the entirely false premise that 10 days of doxycycline ‘cures’ Lyme disease. This tenet has been proven false again and again yet is regurgitated as an unquestionable rule. All you have to do is look around and see thousands still suffering after this supposed ‘gold standard’ therapy.

The authors also state that ‘Chronic Lyme Disease’ (CLD) is ‘used by some to describe individuals with a vague array of symptoms, frequently lacking documentation of exposure to Bb.

So, in paragraph two they already tip their hand that they are simply old school players who buy the clap-trap that Lyme is simple to identify, prove, and treat when everyone and their dog knows this belief belongs in the same category as pixie dust. A test that can be wrong nearly 90% of the time is no test that should be taken seriously by anyone. Diagnosis remains a ‘clinical’ one and anyone who says other wise is an ostrich with their head in the sand.

Important excerpt:

“In this review, we focus on and refer to PTLDS using criteria proposed and generally accepted by most academic and government agencies.4,9-11 Individuals with PTLDS had laboratory and clinically supported evidence of B. burgdorferi infection. They received appropriate early antibiotic therapy9,12 and continued to have or develop new symptoms within 6 months of infection that lasted for a period of at least 6 months, resulting in impaired or declining function.”

This is all I need to know. They will find nothing of value for sick patients. Zip. Nadda.

Until the world wakes up to the uniqueness of this complex illness, we simply circle the drain.

For more:

Category:

Lyme, research

Comments Off on Designing Studies For Post-Treatment Lyme Disease and Other Infection-Associated Chronic Illnesses